Changshu KE. Epidermal growth factor receptor: a key manipulator in molecular pathways of malignant glioma. Oncol Transl Med, 2016, 2: 99-103.
Epidermal growth factor receptor: a key manipulator in molecular pathways of malignant glioma
Received:January 25, 2016  Revised:May 20, 2016
View Full Text  View/Add Comment  Download reader
KeyWord:epidermal growth factor receptor (EGFR); molecular pathways; malignant glioma
Author NameAffiliationE-mail
Changshu KE Dept. of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China 
Hits: 4301
Download times: 4976
      The epidermal growth factor receptor (EGFR) is a member of the ErbB/EGFR family, including EGFR/Her1, ErbB2/Her2, ErbB-3/Her3, and ErbB-4/Her4. EGFR exerts its effects through the receptor tyrosine kinase phosphorylation and activation of important downstream signaling pathways in normal and neoplastic cells, mainly the Ras GTPase/MAP kinase (MAPK), STAT3, and phosphatidylinositide 3 kinase-AKT pathways. EGFR deregulation is common in malignant glioma, especially primary glioblastoma, and exists in three forms: gene overexpression (amplification), autocrine effects of EGFR activation, and activating receptor mutation (EGFRvIII). However, some EGFR abnormalities have also been found in low-grade gliomas, including the nuclear localization of EGFR, expression in the microfoci of anaplastic transformation, and association with neovascularization in the mesenchyma of the glioma, which suggests that some unknown EGFR-related mechanisms are possibly responsible for its central role in the initiation and progression of malignant glioma. Uncovering these mechanisms will have potential value in the development of radiotherapy, chemotherapy, and EGFR-targeted therapy for glioma.